Distinguished in Lung Cancer

Dr. Khaled A. Tolba

Hematology Oncology | Oncology
825 Eastlake Ave E, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Lung Cancer
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Khaled Tolba is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Tolba is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 8 clinical trials in the study of Lung Cancer.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug
Study Drug: INC280
Study Phase: Phase 2
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
Enrollment Status: Terminated
Publish Date: August 08, 2023
Intervention Type: Biological
Study Drug: GRN-1201+Pembrolizumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)
A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 6 Less Clinical Trials

21 Total Publications

First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap.
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap.
Journal: Immunotherapy
Published: September 05, 2025
Similar Doctors
Elite in Lung Cancer
Dr. Christina S. Baik
Oncology | Hematology Oncology
Elite in Lung Cancer
Dr. Christina S. Baik
Oncology | Hematology Oncology

The Association Of University Physicians

325 9th Ave, 
Seattle, WA 
 (1.6 miles away)
206-731-3000
Languages Spoken:
English, Castilian, Hindi, Korean, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Christina Baik is an Oncologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Baik is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Baik is currently accepting new patients.

Elite in Lung Cancer
Dr. Siddhartha Devarakonda
Hematology | Oncology
Elite in Lung Cancer
Dr. Siddhartha Devarakonda
Hematology | Oncology
1221 Madison Street, Arnold Pavilion, Suite 200, 
Seattle, WA 
 (1.2 miles away)
206-386-2424
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Siddhartha Devarakonda is a Hematologist and an Oncologist in Seattle, Washington. Dr. Devarakonda has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Distinguished in Lung Cancer
Dr. Keith D. Eaton
Oncology
Distinguished in Lung Cancer
Dr. Keith D. Eaton
Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-598-4333
Languages Spoken:
English, Filipino, French, Hindi, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Eaton is an Oncologist in Seattle, Washington. Dr. Eaton is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Salivary Gland Tumors, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). Dr. Eaton is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tolba's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile